Atomo Diagnostics (ASX:AT1) ROE % Adjusted to Book Value: -11.52% (As of Dec. 2025)


What is Atomo Diagnostics ROE % Adjusted to Book Value?

Atomo Diagnostics ASX:AT1 ROE % Adjusted to Book Value is -11.52% as of Dec. 2025. The stock has 4 warning signs investors should review.

Atomo Diagnostics's ROE % for the quarter that ended in Dec. 2025 was -51.84%. Atomo Diagnostics's PB Ratio for the quarter that ended in Dec. 2025 was 4.50. Atomo Diagnostics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -11.52%.

Atomo Diagnostics ROE % Adjusted to Book Value Related Terms

Atomo Diagnostics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics ROE % Adjusted to Book Value Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -5.34 -15.99 -59.16 -35.29 -37.35

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.14 -39.83 -39.94 -39.44 -11.52

ASX:AT1 vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, Atomo Diagnostics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atomo Diagnostics ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Atomo Diagnostics's ROE % Adjusted to Book Value falls into.


Atomo Diagnostics ROE % Adjusted to Book Value Calculation

Atomo Diagnostics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-58.27% / 1.56
=-37.35%

Atomo Diagnostics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-51.84% / 4.50
=-11.52%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -11.52% mean?
Atomo Diagnostics (ASX:AT1) has a ROE % Adjusted to Book Value of -11.52% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' ROE % Adjusted to Book Value too high?
Atomo Diagnostics' current ROE % Adjusted to Book Value is -11.52%.
How does Atomo Diagnostics' ROE % Adjusted to Book Value compare to ABT and SYK?
Atomo Diagnostics' ROE % Adjusted to Book Value of -11.52% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Atomo Diagnostics and its competitors. Atomo Diagnostics's current ROE % Adjusted to Book Value is -11.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current ROE % Adjusted to Book Value is -11.52%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current ROE % Adjusted to Book Value is -11.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.